Your browser doesn't support javascript.
loading
Importance of early treatment initiation in the clinical course of multiple sclerosis.
Kavaliunas, Andrius; Manouchehrinia, Ali; Stawiarz, Leszek; Ramanujam, Ryan; Agholme, Jonas; Hedström, Anna Karin; Beiki, Omid; Glaser, Anna; Hillert, Jan.
Afiliação
  • Kavaliunas A; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Manouchehrinia A; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Stawiarz L; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Ramanujam R; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden/Department of Mathematics, KTH Royal Institute of Technology, Stockholm, Sweden.
  • Agholme J; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Hedström AK; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Beiki O; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden/Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Glaser A; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Hillert J; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Mult Scler ; 23(9): 1233-1240, 2017 Aug.
Article em En | MEDLINE | ID: mdl-27754943
OBJECTIVES: The aim of this study was to identify factors influencing the long-term clinical progression of multiple sclerosis (MS). A special objective was to investigate whether early treatment decisions influence outcome. METHODS: We included 639 patients diagnosed with MS from 2001 to 2007. The median follow-up time was 99 months (8.25 years). Cox regression models were applied to identify factors correlating with the outcome variable defined as time from treatment start to irreversible score 4 of the Expanded Disability Status Scale (EDSS). RESULTS: Patients initiated on treatment later had a greater risk of reaching EDSS 4 (hazard ratio of 1.074 (95% confidence interval (CI), 1.048-1.101)), increased by 7.4% for every year of delay in treatment start after MS onset. Patients who started treatment after 3 years from MS onset reached the outcome sooner with hazard ratio of 2.64 (95% CI, 1.71-4.08) compared with the patients who started treatment within 1 year from MS onset. Baseline EDSS and age at onset were found to be predictive factors of disability progression. CONCLUSION: Early treatment initiation was associated with a better clinical outcome. In addition, we confirmed the well-established prognostic factors of late age at onset and early disability.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Índice de Gravidade de Doença / Avaliação de Resultados em Cuidados de Saúde / Progressão da Doença / Intervenção Médica Precoce / Esclerose Múltipla Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Índice de Gravidade de Doença / Avaliação de Resultados em Cuidados de Saúde / Progressão da Doença / Intervenção Médica Precoce / Esclerose Múltipla Tipo de estudo: Observational_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article